Supporting this idea, some studies showed that JNK activation improved the sensitivity to anti-PD-1 therapy in pancreatic and small lung cancer; however, other studies reported that JNK activation increases anti-PD-1 resistance by upregulating PD-L1 expression in glioblastoma and bladder cancer [42–45]. Here, MAPK8 is linked to urinary bladder carcinoma.